降低抗菌素耐药性风险的临床试验
积极的经验性抗生素治疗和治疗持续时间对需要机械通气的肺炎住院患者治疗期间抗生素耐药性出现的影响
研究概览
地位
条件
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Hannover、德国、30625
- Hannover Clinical Trial Center GmbH
-
-
-
-
-
Paris、法国、Cedex 13
- Institut de Cardiologie, Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
California
-
San Mateo、California、美国、94403
- InClin, Inc.
-
-
Florida
-
Gainesville、Florida、美国、32610
- UFL Department of Medicine: Pulmonary, Critical Care and Sleep Medicine
-
-
Georgia
-
Atlanta、Georgia、美国、30322-4250
- Emory University
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University
-
-
Iowa
-
North Liberty、Iowa、美国、52317
- JMI Laboratories
-
-
Missouri
-
Saint Louis、Missouri、美国、63130
- Washington University in St. Louis School of Medicine
-
-
New York
-
New York、New York、美国、10065
- Weill Cornell Medical Center of Cornell University
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Lerner College of Medicine
-
-
-
-
-
Barcelona、西班牙、08035
- Hospital Vall d'Hebron
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
纳入标准:
受试者/受试者的 LAR 的书面知情同意书。
≥ 18 岁因呼吸衰竭需要机械通气且临床怀疑 HABP、HCAP 或 VABP 的住院男性或女性。
在任何患者医疗机构入院后至少 48 小时内肺炎发作或加重,或在疗养院或康复机构发生肺炎并随后转移到急症护理机构
如果妊娠试验为阴性,则具有生育潜力的妇女
在治疗前支气管镜检查进入后 14 天内接受过先前抗菌治疗的受试者只有在受试者没有临床反应的情况下才可以进入。)。 虽然少于 24 小时的预治疗抗生素是优先的,但定量支气管镜 BAL 中 >104 CFU/ml 的恢复将被视为先前治疗无效的主要证据,并允许入组。)
患者应具有支持 HABP/VABP/HCAP 诊断的临床发现:
在开始经验性治疗前 48 小时内,受试者的胸片应显示存在新的或进行性浸润、空洞或积液,提示肺炎
在经验性研究治疗开始前 36 小时内,必须对支气管镜 BAL 液进行定量培养。
VABP 患者的临床肺部感染评分应为 >/= 5。
排除标准:
患有由对美罗培南具有耐药性的病原体(MIC 大于或等于 16µg/ml)或先前美罗培南治疗失败的肺炎的受试者。
对任何研究药物有禁忌症的受试者,特别是已知或疑似过敏或超敏反应的受试者。
怀孕或哺乳期的妇女。
服用抗惊厥药物治疗已知癫痫症的受试者。有癫痫病史且抗癫痫药物治疗情况稳定的患者可由现场调查员酌情参加研究。
患有已知或疑似社区获得性细菌性肺炎(CABP)或病毒性肺炎的受试者;或没有肺炎证据的慢性支气管炎急性加重的受试者。
患有原发性肺癌或其他恶性肿瘤转移到肺部的受试者。
以前参加过这项研究的受试者。
在进入研究前 30 天内服用过研究药物或使用过研究设备的受试者。
具有另一个感染病灶的受试者需要同时使用抗生素,这会干扰对研究药物反应的评估。
患有囊性纤维化、艾滋病的受试者,CD4 淋巴细胞计数
在研究治疗期间生存机会很小的受试者。
APACHE II 得分 >35 的受试者。
具有难以解释对研究药物的反应的潜在病症的受试者。
尽管尝试了液体复苏,但仍有低血压或酸中毒的受试者。 如果他们的低血压得到控制并且酸中毒已经解决,则需要用血管加压药进行持续治疗的受试者将有资格参加该研究。 患有顽固性感染性休克的受试者不符合入组资格。
接受过骨髓移植的受试者。
根据 PaO2/FiO2 比率定义的严重缺氧的受试者
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:静脉注射美罗培南;肠外氨基糖甙类
分配给该组的受试者将收到:
利奈唑胺或万古霉素(根据机构指南)将可用于 MRSA 覆盖范围,以治疗潜在的革兰氏阳性病原体。 |
分配到该组的受试者将接受静脉注射美罗培南(每 8 小时 3 小时输注 2 克)。
其他名称:
肠胃外氨基糖苷类药物(妥布霉素或庆大霉素 5mg/kg IV Q24h 或阿米卡星 20 mg/kg IV Q24h)
MRSA 覆盖范围将提供利奈唑胺或万古霉素(根据机构指南)。
妥布霉素雾化 600mg/天
|
有源比较器:静脉注射美罗培南
分配到该组的受试者将接受静脉注射美罗培南(每 8 小时 3 小时输注 2 克)。 利奈唑胺或万古霉素(根据机构指南)将可用于 MRSA 覆盖以治疗革兰氏阳性病原体。 **注意:双臂均允许经验性 MRSA 覆盖。 对于进入研究的已知或疑似 MRSA 的任何受试者,建议使用这种疗法。 一旦获得微生物学结果,该承保范围可能会由研究人员自行决定终止。 |
MRSA 覆盖范围将提供利奈唑胺或万古霉素(根据机构指南)。
分配到该组的受试者将接受静脉注射美罗培南(每 8 小时 3 小时输注 2 克)。 MRSA 覆盖范围将提供利奈唑胺或万古霉素(根据机构指南)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
受到抑制和出现抵抗的参与者人数
大体时间:注册后最多 28 天
|
耐药性的出现被定义为当在第 5 天/早期拔管的第二次 BAL 程序中评估时,美罗培南 MIC 或氨基糖苷类 MIC 从基线的两倍管稀释度(四倍)的变化。
如果患者有基线 BAL 和第 5 天/提前拔管,并且如果他们在基线和第 1 天/EE 时培养呈阳性,则患者可评估此终点。
|
注册后最多 28 天
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
临床反应
大体时间:治疗结束 - 入组后最多 28 天
|
按疗效终点、治疗组和人群划分的成功缓解患者百分比 (n/N)
|
治疗结束 - 入组后最多 28 天
|
先前接受过抗生素治疗的受试者的临床反应
大体时间:治疗结束 - 入组后最多 28 天
|
按疗效终点、治疗组和人群划分的成功缓解患者百分比 (n/N)
|
治疗结束 - 入组后最多 28 天
|
总体微生物反应
大体时间:治疗结束 - 入组后最多 28 天
|
按疗效终点、治疗组和人群划分的成功缓解患者百分比 (n/N)
|
治疗结束 - 入组后最多 28 天
|
预处理病原体反应
大体时间:治疗结束 - 入组后最多 28 天
|
按疗效终点、治疗组和人群划分的成功缓解患者百分比 (n/N)
|
治疗结束 - 入组后最多 28 天
|
抑制其他革兰氏阴性病原体耐药性的出现
大体时间:第 5 天/提前拔管
|
按疗效终点、治疗组和人群划分的成功缓解患者百分比 (n/N)
|
第 5 天/提前拔管
|
重复阴性培养的发生
大体时间:第 5 天/提前拔管
|
按疗效终点、治疗组和人群划分的成功缓解患者百分比 (n/N)
|
第 5 天/提前拔管
|
死亡
大体时间:14天
|
按疗效终点、治疗组和人群分类的死亡患者百分比 (n/N)
|
14天
|
死亡
大体时间:28天
|
按疗效终点、治疗组和人群分类的死亡患者百分比 (n/N)
|
28天
|
合作者和调查者
调查人员
- 首席研究员:George L Drusano, MD、University of Florida
出版物和有用的链接
一般刊物
- American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416. doi: 10.1164/rccm.200405-644ST. No abstract available.
- Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. doi: 10.1086/516284.
- Bauernfeind A, Jungwirth R. In Vitro Activity of SM 7338 and Imipenem. 28th ICAAC, Los Angeles, October 1988. Abstract 599
- Calandra GB, Hesney M, Brown KR. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial. Clin Ther. 1985;7(2):225-38.
- Clarke AM, Zemcov SJV. SM 7338 (ICI 194,660), A New DHP-1 Stable Carbapenem; In Vitro Activity Against a Wide Range of Canadian Clinical Isolates. 28th ICAAC, Los Angeles, October 1988. Abstract 598.
- Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997 Feb;24 Suppl 2:S266-75. doi: 10.1093/clinids/24.supplement_2.s266.
- Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 2003 Aug;23(8):988-91. doi: 10.1592/phco.23.8.988.32878.
- Data on file. Drug Development Department, AstraZeneca Pharmaceuticals, Wilmington,DE 19897.
- Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S42-50. doi: 10.1086/344653.
- Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother. 2009 Jun;53(6):2266-73. doi: 10.1128/AAC.01680-08. Epub 2009 Mar 16.
- Edwards JR, Wannop C. SM 7338, A New Carbapenem Antibacterial: In Vitro Activity Against Imipenem-Resistant Ps. aeruginosa. 27th ICAAC, New York October 1987, Abstract 754.
- Edwards JR, Turner PJ, Withnell ES, et al. SM 7338, A New Carbapenem Antibacterial: In Vitro Activity Against Bacterial Strains of Clinical Origins. 27th ICAAC, New York, October 1987, Abstract 755.
- Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindey AJ, Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother. 1989 Feb;33(2):215-22. doi: 10.1128/AAC.33.2.215.
- Fagon JY, Chastre J, Novara A, Medioni P, Gibert C. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med. 1993;19(3):137-44. doi: 10.1007/BF01720528.
- Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994 Mar;38(3):547-57. doi: 10.1128/AAC.38.3.547.
- Fukasawa M, Sumita Y, Tada E, et al. SM 7338, A New Carbapenem Antibacterial: In Vitro Activity Against 1607 Clinical Strains of Gram-Positive and Gram-Negative Pathogens. 27th ICAAC, New York, October 1987, Abstract 753.
- Fukasawa M, Tada E, Nouda H, et al. Induction and Inhibition of b-Lactamases by SM 7338; A Novel Carbapenem Antibacterial. 28th ICAAC, Los Angeles, October 1988. Abstract 606.
- Hamacher J, Vogel F, Lichey J, Kohl FV, Diwok K, Wendel H, Lode H. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group. J Antimicrob Chemother. 1995 Jul;36 Suppl A:121-33. doi: 10.1093/jac/36.suppl_a.121.
- Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1249-56. doi: 10.1164/ajrccm.159.4.9807050.
- Investigational Brochure, Drug Development Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19897.
- Jones RN, Barry AL, et al. Antimicrobial Activity of SM 7338, A New DHP-1 Stable Carbapenem. 28th ICAAC, Los Angeles, October 1988. Abstract 597.
- Kayser FH, Morenzoni G. Activity of SM 7338, A New Carbapenem Antibacterial Against Gram-Positive Bacteria. 28th ICAAC, Los Angeles, October 1988. Abstract 603.
- Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999 Feb;115(2):462-74. doi: 10.1378/chest.115.2.462.
- Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 1995 Dec;108(6):1655-62. doi: 10.1378/chest.108.6.1655.
- Lancero MG, Young LS. In Vitro Studies with SM 7338; A Novel Carbapenem with Broad Bactericidal Activity. 28th ICAAC, Los Angeles, October 1988. Abstract 602.
- Lode H, Hamacher J, Eller J, Schaberg T. Changing role of carbapenems in the treatment of lower respiratory tract infections. Scand J Infect Dis Suppl. 1995;96:17-23.
- Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997 Mar;111(3):676-85. doi: 10.1378/chest.111.3.676.
- McEachern R, Campbell GD Jr. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am. 1998 Sep;12(3):761-79, x. doi: 10.1016/s0891-5520(05)70209-9.
- Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest. 1992 Nov;102(5 Suppl 1):557S-564S. doi: 10.1378/chest.102.5_supplement_1.557s. No abstract available.
- Moellering RC Jr, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother. 1989 Sep;24 Suppl A:1-7. doi: 10.1093/jac/24.suppl_a.1.
- Neu HG, Saha G, Chin NX. In Vitro Activity of SM 7338; A New Carbapenem, Compared with Other Antibacterials Against Multiply Resistant Bacteria. 28th ICAAC, Los Angeles, October 1988. Abstract 601.
- Nord CE, Lindmark A, Persson I. Susceptibility of Anaerobic Bacteria to SM 7338. 28th ICAAC, Los Angeles, October 1988. Abstract 596.
- Okuda T, Fukasawa M, Tanio T, et al. SM 7338, A New Carbapenem Antibacterial: In Vitro and In Vivo Antibacterial Activities. 27th ICAAC, New York, October 1987. Abstract 757.
- Quinn JP, Studemeister AE, DiVincenzo CA, Lerner SA. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis. 1988 Jul-Aug;10(4):892-8. doi: 10.1093/clinids/10.4.892.
- Sanford Guide to Antimicrobial Therapy. Thirty-third Edition, 2003. Gilbert DN, Moellering RC, Sande MA.
- Scheld WM, Mandell GL. Nosocomial pneumonia: pathogenesis and recent advances in diagnosis and therapy. Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S743-51. doi: 10.1093/clinids/13.supplement_9.s743.
- Slaney L, Chubb H, Mohammed Z, et al. In Vitro Activity of SM 7338 Against Neisseria gonorrhoeae (Gc), Haemophilus ducreyi (Hd) and Haemophilus influenzae. 28th ICAAC, Los Angeles, October 1988. Abstract 604.
- Strasbaugh LJ. Nosocomial repiratory infections. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. Philadelphia: Churchill Livingstone, 2000: 3021-3026.
- Sumita Y, Fukasawa M, Okunda T. SM 7338, A New Carbapenem Antibacterial: Affinities for PBP's and Morphological Changes. 27th ICAAC, New York, October 1987. Abstract 756.
- Sumita Y, Inoue M, Mitsuhashi S. In Vitro Antibacterial Activity of SM 7338. 28th ICAAC, Los Angeles, October 1988. Abstract 600.
- Sunagawa M, Matsumura H, Inoue T, et al. SM 7338, A New Carbapenem Antibacterial: Structure-Activity Relations and Physiochemical Properties. 27th ICAAC, New York, October 1987. Abstract 752.
- Talke H.S.G.E. Enzymatische harnstoffbestimmung im blut and serum im optischem test nach Warburg. Klin Wochschr 1965;43:174.
- Torres A, Aznar R, Gatell JM, Jimenez P, Gonzalez J, Ferrer A, Celis R, Rodriguez-Roisin R. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis. 1990 Sep;142(3):523-8. doi: 10.1164/ajrccm/142.3.523.
- Torres A, Bauer TT, Leon-Gil C, Castillo F, Alvarez-Lerma F, Martinez-Pellus A, Leal-Noval SR, Nadal P, Palomar M, Blanquer J, Ros F. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax. 2000 Dec;55(12):1033-9. doi: 10.1136/thorax.55.12.1033.
- Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998 Feb;157(2):531-9. doi: 10.1164/ajrccm.157.2.9705064.
- Vetter N. The Use of Meropenem ('Merrem'/'Meronen') in the Therapy of Hospital-acquired Lower Respiratory Infections: a Review of Clinical Experience. 18th International Congress of Chemotherapy, Stockholm, Sweden, 27 June-2 July, 1993. Abstract 70.
- Wise R, Andrews JM, Ashby JP. The Bactericidal Activity of the Carbapenem, SM 7338, Alone and in Combination. 28th ICAAC, Los Angeles, October 1988. Abstract 605.
- World Health Organization. Draft Global Strategy for the Containment of Antimicrobial Resistance. Available on the Internet at http://www.who.int/emc/amr.htm
- Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C. Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Erratum In: Antimicrob Agents Chemother. 2018 Mar 27;62(4):
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
静脉注射美罗培南的临床试验
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); Department of Health and Human Services完全的艾滋病毒感染美国, 津巴布韦, 肯尼亚, 南非
-
Asir John SamuelMaharishi Markendeswar University (Deemed to be University)招聘中
-
Prometheus Biosciences, Inc., a subsidiary of Merck...Altasciences Company Inc.完全的
-
International AIDS Vaccine InitiativeBeth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard; University of Texas... 和其他合作者完全的
-
SpineSave AG尚未招聘脊椎关节炎 | 腰椎不稳 | 退行性脊椎滑脱 | 退行性腰椎管狭窄症 | 椎间盘病 | 小关节关节病